Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Biotechnology

Health & Wellness

Health Care

Pharmaceutical

Amolyt Pharma

Thierry Abribat

Benedicte Gagnere

michel ovize

Blandine WEISS

Taha Ould Rouis, MD

Caroline Robo (Fesquet)

Patrick Loustau

Michael Culler

Laetitia Ouafki

Héloïse Boullet

Guillaume Ravel, PharmD, PhD, DABT

Delphine Martinez

Damien Aumaille

Clémentine Chalmey

Aurélie MILLERAT

The CMC Team at Amolyt Pharma focuses on Chemistry, Manufacturing, and Controls for their peptide-based therapies. They are responsible for ensuring the development, production, and quality control of drug substances and products like AZP-3601 and AZP-3404, ensuring they meet regulatory standards and are safe and effective for treating rare endocrine and metabolic disorders.

CMC Team

Clinical Management Team

Leadership Team

CMC Team

About

Team members

Other teams at Amolyt Pharma

Clinical Management Team

Leadership Team